Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · August 29, 2019

Trastuzumab Biosimilar vs Reference Trastuzumab in the Neoadjuvant Setting for HER2-Positive Breast Cancer

European Journal of Cancer

 

Additional Info

European Journal of Cancer
Three-Year Follow-Up From a Phase 3 Study of SB3 (a Trastuzumab Biosimilar) Versus Reference Trastuzumab in the Neoadjuvant Setting for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Eur. J. Cancer 2019 Oct 01;120(xx)1-9, X Pivot, M Pegram, J Cortes, D Lüftner, GH Lyman, G Curigliano, I Bondarenko, YC Yoon, Y Kim, C Kim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading